Wegovy HD (Semaglutide 7.2 mg): What the STEP UP Trial Shows
Wegovy HD delivers semaglutide 7.2 mg — the FDA's newest high-dose obesity drug. STEP UP showed up to 20.7% weight loss. Here's the evidence, dosing, and safety.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on June 30, 2026
Our medical review process ensures clinical accuracy and patient safety.
For people who plateau on standard-dose semaglutide, a stronger option now exists. Wegovy HD delivers semaglutide 7.2 mg once weekly — three times the 2.4 mg dose that has anchored obesity care since 2021 — and the FDA approved it on March 20, 2026, with nationwide availability following in early April. The approval rests on STEP UP, a phase 3b trial in which the higher dose drove mean weight loss of up to 20.7% over 72 weeks. This article breaks down what that number actually means, who the drug is for, and how its safety profile differs from the dose most patients already know.
Evidence: "Once-weekly semaglutide 7·2 mg led to significantly greater reductions in bodyweight than semaglutide 2·4 mg and placebo in adults with obesity, with a safety profile consistent with the GLP-1 receptor agonist class." — Wharton S, et al. Lancet Diabetes Endocrinol. 2025. DOI: 10.1016/S2213-8587(25)00226-8
What Is Wegovy HD (Semaglutide 7.2 mg)?
Wegovy HD is a higher-dose formulation of semaglutide, the same GLP-1 receptor agonist sold as Wegovy 2.4 mg and Ozempic. The active molecule is identical; the difference is concentration. Where the original maintenance dose tops out at 2.4 mg once weekly, Wegovy HD reaches 7.2 mg — the highest weekly semaglutide dose ever cleared for weight management.
The FDA approved it as the fourth product under the Commissioner's National Priority Voucher pilot, a fast-track program that compressed the review to 54 days from filing. The approved indication is narrow on purpose: Wegovy HD is an adjunct to a reduced-calorie diet and increased physical activity for additional weight loss in adults with obesity who have already tolerated semaglutide 2.4 mg for at least four weeks, and for long-term maintenance of that weight reduction. It is a step-up option, not a starting dose.
For readers new to this class, our guide to what semaglutide is covers how the molecule suppresses appetite and slows gastric emptying. Wegovy HD does not change that mechanism — it amplifies the same signaling that lower doses rely on.
Inside the STEP UP Trial
STEP UP was the registration trial behind the approval. It enrolled 1,407 adults with obesity (BMI ≥30) and without type 2 diabetes across 11 countries between January 2023 and November 2024. Participants had a mean age of 47, a mean baseline weight of 113 kg, and 73.7% were women. They were randomized to once-weekly semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo — each paired with a structured lifestyle intervention — and followed for 72 weeks.
How much more weight?
The trial reported two complementary estimands. The treatment-policy estimand reflects real-world results regardless of whether participants stayed on the drug; the trial-product estimand estimates the effect assuming full adherence. Both favored the higher dose.
| Outcome (72 weeks) | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Mean weight loss (treatment-policy) | −18.7% | −15.6% | −3.9% |
| Mean weight loss (trial-product) | −20.7% | −17.5% | −2.4% |
| Achieved ≥25% weight loss | 33.2% | 16.7% | 0% |
| Returned to BMI <30 | 43.2% | — | — |
Evidence: "A significantly greater proportion of participants receiving semaglutide 7·2 mg achieved bodyweight reductions of 25% or more compared with those receiving 2·4 mg or placebo." — Wharton S, et al. Lancet Diabetes Endocrinol. 2025. DOI: 10.1016/S2213-8587(25)00226-8
The headline is the roughly three-percentage-point gain over the 2.4 mg dose — modest on average, but meaningful at the tail. Doubling the share of people who lose a quarter of their body weight (33.2% vs 16.7%) matters most for patients whose comorbidities demand deeper weight reduction.
Beyond the scale
Weight is only part of the picture. STEP UP also showed superior reductions in waist circumference and HbA1c with the 7.2 mg dose, and 43.2% of participants dropped below the obesity threshold entirely. These cardiometabolic shifts echo the broader semaglutide evidence base. In the SELECT cardiovascular outcomes trial, semaglutide 2.4 mg cut the risk of major adverse cardiovascular events in adults with obesity and established heart disease — a benefit that helped redefine GLP-1 therapy as more than cosmetic.
Evidence: "Among patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, semaglutide 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke." — Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563
Whether the 7.2 mg dose extends that cardiovascular protection further has not been tested in a dedicated outcomes trial, so its benefits beyond weight and glycemia remain inferred rather than proven.
A Companion Trial in Type 2 Diabetes
People with type 2 diabetes typically lose less weight on GLP-1 drugs than those without it. The STEP UP T2D trial tested the 7.2 mg dose in 512 adults with both obesity and type 2 diabetes. The higher dose produced 13.2% mean weight loss and a 1.5 percentage-point reduction in HbA1c versus placebo — strong glycemic control alongside meaningful weight reduction, though the absolute weight loss trailed the diabetes-free population, consistent with prior trials.
Evidence: "In adults with obesity and type 2 diabetes, once-weekly semaglutide 7·2 mg significantly reduced bodyweight and HbA1c compared with placebo over 72 weeks." — Lingvay I, et al. Lancet Diabetes Endocrinol. 2025. DOI: 10.1016/S2213-8587(25)00225-6
How Wegovy HD Fits Into Treatment
Wegovy HD is positioned as an escalation, not a replacement. The titration path is straightforward: tolerate semaglutide 2.4 mg for at least four weeks, then — if you and your clinician decide more weight loss is warranted — step up to 7.2 mg once weekly, the maximum dose. This mirrors how clinicians already manage the standard semaglutide titration schedule, simply adding a higher rung at the top.
The best candidates are people who have responded to 2.4 mg but stalled short of their goal — the same population that often confronts a weight-loss plateau. It is worth setting expectations honestly: the average incremental benefit is a few percentage points, not a transformation. For someone already at 15% weight loss, 7.2 mg may unlock another increment; it will not rescue a non-responder who never tolerated the lower dose.
The original STEP 1 trial established the 2.4 mg benchmark that Wegovy HD now builds on.
Evidence: "The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% in the placebo group." — Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
Safety and Tolerability at the Higher Dose
Most adverse events with Wegovy HD were the familiar gastrointestinal complaints of GLP-1 therapy — nausea, vomiting, diarrhea, constipation, and abdominal pain — and most were mild to moderate. They were, however, more frequent at the higher dose: GI events occurred in 70.8% of the 7.2 mg group versus 61.2% with 2.4 mg and 42.8% with placebo. Our overview of GLP-1 side effects and practical nausea management strategies applies equally to Wegovy HD.
One signal deserves specific attention. Dysesthesia — an altered or uncomfortable skin sensation such as tingling or heightened sensitivity — appeared in 22.9% of the 7.2 mg group, compared with 6% on 2.4 mg and 0.5% on placebo. It is rarely serious, but the steep dose-dependence is new information that did not surface prominently at lower doses, and patients stepping up should know to report it.
Evidence: "The safety profile of semaglutide 7·2 mg was consistent with that of the GLP-1 receptor agonist class, with a higher frequency of gastrointestinal and dysesthesia-related events than with semaglutide 2·4 mg." — Wharton S, et al. Lancet Diabetes Endocrinol. 2025. DOI: 10.1016/S2213-8587(25)00226-8
Wegovy HD vs the Competition
Wegovy HD does not arrive in an empty field. Tirzepatide — the dual GIP/GLP-1 agonist sold as Zepbound — outperformed semaglutide 2.4 mg in the head-to-head SURMOUNT-5 trial, raising the bar for what counts as best-in-class. The relevant question for clinicians is whether pushing semaglutide to 7.2 mg narrows that gap. STEP UP and SURMOUNT-5 were separate trials with different populations, so cross-trial comparisons are imperfect, but they frame the choice.
Evidence: "Tirzepatide was superior to semaglutide with respect to the percentage reduction in body weight at week 72 among adults with obesity who did not have diabetes." — Aronne LJ, et al. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2416394
For a fuller breakdown, see our comparison of tirzepatide versus semaglutide. Durability is the other axis that matters: long-term data show semaglutide's effect holds with continued treatment.
Evidence: "Semaglutide 2.4 mg produced sustained, clinically relevant weight loss over 104 weeks, with a mean change in body weight of −15.2% versus −2.6% with placebo." — Garvey WT, et al. Nat Med. 2022;28(10):2083-2091. DOI: 10.1038/s41591-022-02026-4
Key Takeaways
Wegovy HD gives clinicians a higher ceiling for semaglutide without introducing a new molecule or mechanism. STEP UP shows the 7.2 mg dose delivers up to 20.7% mean weight loss and roughly doubles the share of patients reaching ≥25% loss, at the cost of more frequent gastrointestinal symptoms and a notable dysesthesia signal. It is built for one job — squeezing additional weight loss out of patients who already tolerate 2.4 mg but want more — and the evidence supports that specific use rather than first-line treatment. As always, the dose decision belongs in a conversation with your prescriber, weighed against tolerability, cost, and alternatives like tirzepatide.
References
- Wharton S, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025. DOI: 10.1016/S2213-8587(25)00226-8
- Lingvay I, et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025. DOI: 10.1016/S2213-8587(25)00225-6
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. DOI: 10.1056/NEJMoa2416394
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. DOI: 10.1038/s41591-022-02026-4
Last updated: 2026-06-30 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Emily Rodriguez
Senior Medical Writer, MPH, RD
Emily Rodriguez is a registered dietitian and public health specialist. She translates complex medical research into accessible, actionable content for patients and healthcare providers.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.